New drug combo aims to keep lung cancer in check longer

NCT ID NCT07459634

Recruiting now Disease control Sponsor: Jazz Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 21, 2026 · Updated 3 times

Summary

This Phase 2 trial tests whether combining lurbinectedin (Zepzelca) with durvalumab (Imfinzi) as maintenance therapy can delay cancer growth in people with extensive-stage small-cell lung cancer whose disease has not worsened after initial chemotherapy plus durvalumab. About 50 participants will receive the two drugs intravenously. The main goal is to see how many patients remain progression-free after a set time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lurbinectedin (Zepzelca) and durvalumab (Imfinzi)
What this could lead to: If successful, this combination could offer a new maintenance option to delay cancer progression in patients with extensive-stage small-cell lung cancer.
What could go wrong: This is an early Phase 2 trial with only 50 participants and no control group, so results may not confirm benefit. Side effects from the drug combination are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Contacts and locations

Locations

Cancer Specialists of North Florida
RECRUITING

Jacksonville, Florida, 32256, United States
Carolina Blood and Cancer Care
RECRUITING

Rock Hill, South Carolina, 29732, United States
Emory University
RECRUITING

Atlanta, Georgia, 30322, United States
Valkyrie Clinical Trials, Inc.
RECRUITING

Los Angeles, California, 90067, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.